Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks

TipRanksNov 13 17:45 · Ratings

Express News | Longboard Pharmaceuticals Initiates Phase 3 Deep Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (Dees)

BreakingsNov 12 21:30

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

BusinesswireNov 12 21:30

Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Hold Rating

Futu NewsNov 11 20:34 · Ratings

Longboard Pharmaceuticals Advances Neurological Treatments

TipRanksNov 9 12:06

Longboard Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

SECNov 8 05:19 · Announcements